Back to Search

Petrelintide for Weight Management in Type 2 Diabetes

A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes

Recruiting Phase 3 Interventional Study
Obesity or Overweight Type 2 Diabetes
More trials: Diabetes clinical trials· Diabetes trials in California
Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 3
Study type
Interventional
Purpose
Treatment
Participants needed
600 (estimated)
Sponsor
Hoffmann-La Roche · Industry
Who this trial is looking for

This trial is looking for people who are overweight or obese and have type 2 diabetes. Participants will take petrelintide or a placebo while following a lower-calorie diet and exercising more.

Are You a Good Fit for This Trial?

You may be able to join if

  • I have a BMI of 27 or higher
  • I have been diagnosed with type 2 diabetes
  • My HbA1c level is between 6.5% and 10%
  • I have been managing my diabetes with diet and exercise, basal insulin, or certain oral medications for at least 90 days
  • I have tried to lose weight through diet before

You may not be able to join if

  • I have eye problems related to diabetes
  • I have taken petrelintide or other similar medications before

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial

This study will evaluate the efficacy and safety of petrelintide compared with placebo, in conjunction with a reduced-calorie diet and increased physical activity, for weight management in participants living with overweight or obesity and with Type 2 Diabetes (T2D).

Trial Locations

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Participants with BMI ≥ 27 kg/m² * T2D diagnosis as per World Health Organization (WHO) classification (or other locally applicable standards) with HbA1c ≥ 6.5% to ≤ 10% (48-86 mmol/mol), measured by the central laboratory at screening * Stable treatment with either diet and e…
Contacts

Reference Study ID Number: CC46369 https://forpatients.roche.com/No attachments to email below.

888-662-6728 (U.S. and Canada)

global-roche-genentech-trials@gene.com

CONTACT

Fastest Response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry

CONTACT

NCT ID: NCT07843485 Source: ClinicalTrials.gov